171 related articles for article (PubMed ID: 38387906)
21. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia.
Aiba M; Shigematsu A; Suzuki T; Miyagishima T
Ann Hematol; 2023 Mar; 102(3):541-546. PubMed ID: 36646889
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
23. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.
Stevens BM; Jones CL; Pollyea DA; Culp-Hill R; D'Alessandro A; Winters A; Krug A; Abbott D; Goosman M; Pei S; Ye H; Gillen AE; Becker MW; Savona MR; Smith C; Jordan CT
Nat Cancer; 2020 Dec; 1(12):1176-1187. PubMed ID: 33884374
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis.
Kwag D; Cho BS; Bang SY; Lee JH; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Blood Cancer J; 2022 Dec; 12(12):169. PubMed ID: 36529771
[TBL] [Abstract][Full Text] [Related]
25. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
Pollyea DA; Winters A; McMahon C; Schwartz M; Jordan CT; Rabinovitch R; Abbott D; Smith CA; Gutman JA
Bone Marrow Transplant; 2022 Feb; 57(2):160-166. PubMed ID: 34645926
[TBL] [Abstract][Full Text] [Related]
26. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
29. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Arora S; Zainaldin C; Bathini S; Gupta U; Worth S; Bachiashvili K; Bhatia R; Godby K; Jamy O; Rangaraju S; Diamond B; Oliver JD; Salzman D; Di Stasi A; Vachhani P
Leuk Res; 2022 Jun; 117():106844. PubMed ID: 35487134
[TBL] [Abstract][Full Text] [Related]
30. [Clinical Observation of Venetoclax Combined with Demethylating Agents on the Treatment of Relapsed/Refractory Acute Myeloid Leukemia].
Wang Y; Huang SL; Zhang XX; Bian MR; Lin GQ; Si YJ; Zhang B; Wan Y; Wang L; Zhang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):327-332. PubMed ID: 37096501
[TBL] [Abstract][Full Text] [Related]
31. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Matthews AH; Perl AE; Luger SM; Loren AW; Gill SI; Porter DL; Babushok DV; Maillard IP; Carroll MP; Frey NV; Hexner EO; Martin ME; McCurdy SR; Stadtmauer EA; Paralkar VR; Bruno XJ; Hwang WT; Margolis D; Pratz KW
Blood Adv; 2022 Jul; 6(13):3997-4005. PubMed ID: 35507945
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of venetoclax combined azacitidine in newly diagnosed acute myeloid leukemia unfit for standard chemotherapy: a single center experience].
Sun L; Ye SJ; Zhou N; Han XZ; Qi JX; Liu XJ; Luo JM; Yang L
Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):826-832. PubMed ID: 36709196
[No Abstract] [Full Text] [Related]
33. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
35. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
Venugopal S; Shoukier M; Konopleva M; Dinardo CD; Ravandi F; Short NJ; Andreeff M; Borthakur G; Daver N; Pemmaraju N; Sasaki K; Montalban-Bravo G; Marx KR; Pierce S; Popat UR; Shpall EJ; Kanagal-Shamanna R; Garcia-Manero G; Kantarjian HM; Kadia TM
Cancer; 2021 Oct; 127(19):3541-3551. PubMed ID: 34182597
[TBL] [Abstract][Full Text] [Related]
36. [Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
Kunisada K; Matsuoka A; Yoshida S; Taoka T
Rinsho Ketsueki; 2022; 63(12):1621-1625. PubMed ID: 36653133
[TBL] [Abstract][Full Text] [Related]
37. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 Infection in Patients Treated with Azacitidine and Venetoclax for Acute Leukemia: A Report of a Case Series Treated in a Single Institution.
Drozd-Sokołowska J; Mądry K; Barankiewicz J; Kobylińska K; Biecek P; Rytel J; Karakulska-Prystupiuk E; Skwierawska K; Salomon-Perzyński A; Stokłosa T; Basak GW
Chemotherapy; 2023; 68(1):16-22. PubMed ID: 36103840
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR
Front Oncol; 2022; 12():858202. PubMed ID: 35433414
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study.
You L; Liu Y; Mai W; Xie W; Zhou D; Mao L; Chen L; Zhou X; Ma L; Zheng X; Wei J; Lou Y; Ye X; Tong H; Jin J; Meng H
Eur J Cancer; 2024 May; 202():113979. PubMed ID: 38471289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]